Loading...
Loading...
AGEN| Name | Value |
|---|---|
| Revenues | 25.7M |
| Cost of Revenue | 27.0M |
| Gross Profit | -1.3M |
| Operating Expense | 15.4M |
| Operating I/L | -16.7M |
| Other Income/Expense | -13.3M |
| Interest Income | 0.0M |
| Pretax | -30.0M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -28.0M |
Agenus Inc. is a clinical-stage immuno-oncology company that develops and commercializes immuno-oncology products globally. The company's offerings include Retrocyte Display, an antibody expression platform, and vaccine programs such as Prophage vaccine candidate and QS-21 Stimulon adjuvant. Agenus also has a diverse pipeline of immunotherapies in various stages of development, including anti-PD-1, anti-CTLA-4, anti-CD137, and other monoclonal antibodies targeting cancer and infectious diseases. The company generates revenue through collaborations with pharmaceutical companies and the potential future commercialization of its immunotherapy products.
